Alimera faces NICE set back with Iluvien
This article was originally published in Scrip
NICE, the health technology appraisal body for England and Wales, has issued draft guidance declining to recommend Alimera's Iluvien (fluocinolone acetonide) for treating chronic diabetic macular oedema (DMO). The manufacturer's economic modelling fell short, while the firm had not submitted evidence that accurately reflected clinical practice, said the institute.
You may also be interested in...
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.